However, normal expression of VSIG-3 is restricted to brain and testis tissues, and though VSIG-3 upregulation has been observed in gastric and hepatocellular carcinomas, its expression has not been reported in normal immune cells, limiting the relevance of this VISTA binding partner in other settings or cancers. The gene discussed is IGSF11; the disease is cancer.